This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.


01Feb 2019

Back to Seminars overview

NKI seminar by Matti Rookus

Matti Rookus
Netherlands Cancer Institute, Amsterdam, The Netherlands

Which factors push the risk of breast cancer to be this high? - the population and individual perspective

Friday, February 1st, 2019, 11.00 hrs
Piet Borst Auditorium

Matti Rookus
First, in the national Hereditary Breast and Ovarian cancer study Netherlands (HEBON) we enrolled members of high risk families tested for BRCA1/2 mutations. With this study we actively participate in two international initiatives, the prospective International BRCA1/2 Carrier Cohort Study (IBCCS, coordinated at NKI) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, epidemiologic part, coordinated at NKI).

We aim to develop a risk prediction model that incorporates Dutch baseline cancer risks and hormonal/lifestyle/genetic risk factors, to be used in the clinical genetic practice. HEBON/IBCCS/CIMBA are also a resources for studies on gene-gene and treatment-gene interactions, studies on the late health effects of prophylactic surgeries on breasts and ovaries, and studies on the psychological impact of genetic testing and the subsequent decision-making processes

Secondly, we focus on thein uteroperiod as the time window of interest by investigating a cohort of 12,000 women exposed to Diethylstilbestrolin utero(DES daughters).


Share this page